Alnylam Pharmaceuticals, Inc. (ALNY)

177,26 +2,24 (+1,28%) Börsenschluss: 04:00PM EST

Alnylam Pharmaceuticals, Inc.

675 West Kendall Street
Henri A. Termeer Square
Cambridge, MA 02142
United States
617 551 8200
https://www.alnylam.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 2.002

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Yvonne L. Greenstreet M.B.A., MBChB	CEO & Director	2,09M	N/A	1963
Mr. Jeffrey V. Poulton M.B.A.	CFO & Executive VP	972,35k	N/A	1968
Ms. Indrani M. Lall Franchini J.D.	Executive VP, Chief Legal Officer & Secretary	958,96k	N/A	1972
Dr. Akshay K. Vaishnaw M.D., Ph.D.	Chief Innovation Officer	1,24M	848,93k	1963
Dr. Pushkal P. Garg M.D.	Chief Medical Officer and Executive VP of Development & Medical Affairs	1M	N/A	1968
Mr. Timothy J. Maines	Chief Technical Operations & Quality Officer	N/A	N/A	N/A
Dr. Kevin Joseph Fitzgerald Ph.D.	Senior VP, Head of Research & Chief Scientific Officer	N/A	N/A	1968
Ms. Christine Regan Lindenboom	Senior VP of Investor Relations & Corporate Communications	N/A	N/A	1981
Mr. Piyush Sharma J.D.	Chief Ethics & Compliance Officer	N/A	N/A	N/A
Mr. Evan Lippman	Chief Corporate Development & Strategy Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Alnylam Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Dezember 2023, lautet 5. Die grundlegenden Scores sind Audit: 8, Vorstand: 2, Shareholderrechte: 6, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.